FindTrial
Sign In

clinical validation to evaluate efficacy and safety of unani pharmacopeial formulation -Qurs -e-dawa-ul-shifa in zightuddam qawi(hypertension)

Clinical validation study to evaluate the efficacy and safety of unani pharmacopoeical formulation-Qurs-e-Dawa-ul-Shifa in Zightuddam Qawi(Hypertension) - HTN

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/04/032863
Enrollment
110
Registered
2021-04-16
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: single arm study-Qurs -e-Dawa-ul-Shifa: unani pharmacopeial fprmulation-Qurs -e-Dawa-ul-Shifa in Tablet form orally two tablets once daily half an hour after breakfast Intervention2: Qu

Sponsors

CCRUM
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Following are inclusion criteria: 1 Subjects of either sex in the age group of 18-65 years. 2 Subjects of primary hypertension 3 Subjects of Grade- 1 Hypertension with Systolic BP [130–139]/ Diastolic BP [80–89] 4 Presence of any of the following symptoms and signs: 1 Suda(Headache) 2 Duwar(Vertigo) 3 Khafaqan(Palpitation) 4 Kasal (Laziness) 5 Takan(Fatigue) • Waj-us-sadr(Chest pain) • Kasrat-e-baul(Polyurea) • NabzMumtali (Pulsusplenus)

Exclusion criteria

Exclusion criteria: Patients will be excluded who have any or more of the following conditions: 1. Pregnant and lactating women 2. Chronicity of disease more than 10 years 3. Subjects with SBP =140 mmHg and Diastolic BP >90 mmHg 4. Subjects with Secondary Hypertension 5. Subjects taking any other medication affecting blood pressure like NSAIDs and OCPs in females 6. Obese subjects – BMI >30 7. Systemic diseases requiring long term-treatment, e.g., DM-II, Malignancy, Epilepsy, cardiac and kidney diseases. 8. Subjects with Sinus Bradycardia, i.e., pulse rate less than 60/min

Design outcomes

Primary

MeasureTime frame
Reduction in systolic and diastolic Blood pressureTimepoint: baseline,day 14,day 28,day 42,day 56,day 70,day 84—

Secondary

MeasureTime frame
reduction in symptomsTimepoint: reduction in symptoms in 12 weeks—

Countries

India

Contacts

Public ContactDr Huma

Regional research institute of unani medicine Srinagar/CCRUM

humaccrum@gmail.com9796550059

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026